Cue Biopharma, Inc. releases its Q3 results, showcasing progress in pharmaceutical preparations and financial agreements.
| Name | Cue Biopharma, Inc. |
|---|---|
| CIK | 0001645460 |
| Tickers | CUE |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 473324577 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 617-949-2680 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Cue Biopharma, Inc. releases its Q3 results, showcasing progress in pharmaceutical preparations and financial agreements.
Cue Biopharma, Inc. announces its latest financial results, signaling strategic shifts in its operations within the pharmaceutical preparations sector.
Cue Biopharma's Ray Sumita sells shares to meet tax obligations, reflecting compliance with company policies in the pharmaceutical preparations sector.
558 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | 10-Q | 10-Q | 0001193125-26-463755 | 001-38327 | 261562456 | 34 | 14813162 | 1 | 1 | |
| 2026-11-16 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-463741 | 001-38327 | 261562365 | 34 | 477636 | 1 | 1 |
| 2026-11-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-005293 | 005-90232 | 261559142 | 34 | 11511 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000938206-26-000052 | 005-90232 | 261556310 | 34 | 7368 | |||
| 2026-11-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-005042 | 005-90232 | 261555061 | 34 | 14893 | |||
| 2026-11-10 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001420506-26-002561 | 005-90232 | 261541337 | 34 | 11074 | |||
| 2026-10-14 | 4 | xslF345X06/form4-10152026_011030.xml | 0001579629-26-000012 | 5381 | ||||||
| 2026-10-14 | 4 | xslF345X06/form4-10152026_011010.xml | 0002138368-26-000009 | 5381 | ||||||
| 2026-10-14 | 4 | xslF345X06/form4-10152026_011031.xml | 0001725092-26-000019 | 6872 | ||||||
| 2026-10-13 | 144 | xsl144X01/primary_doc.xml | 0001725092-26-000017 | 001-38327 | 261458107 | 33 | 6566 | |||
| 2026-10-13 | 144 | xsl144X01/primary_doc.xml | 0001579629-26-000010 | 001-38327 | 261458102 | 33 | 5878 | |||
| 2026-10-08 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001213900-26-107721 | 005-90232 | 261448316 | 34 | 32327 | |||
| 2026-09-21 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-26-396094 | 001-38327 | 261392307 | 34 | 10521230 | 1 | 1 |
| 2026-08-28 | 4/A | xslF345X06/form4a-08282026_090818.xml | 0002059447-26-000006 | 5656 | ||||||
| 2026-08-28 | 4/A | xslF345X06/form4a-08282026_090821.xml | 0001974756-26-000006 | 5660 | ||||||
| 2026-08-21 | SCHEDULE 13D | xslSCHEDULE_13D_X02/primary_doc.xml | 0001725092-26-000015 | 005-90232 | 261305477 | 34 | 15062 | |||
| 2026-08-20 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-002724 | 333-298266 | 261301601 | 33 | 1787 | ||
| 2026-08-18 | CORRESP | filename1.htm | 0001193125-26-355392 | 8263 | ||||||
| 2026-08-17 | 4 | xslF345X06/form4-08172026_100832.xml | 0001579629-26-000008 | 13799 | ||||||
| 2026-08-17 | 4 | xslF345X06/form4-08172026_100852.xml | 0002138368-26-000007 | 13796 | ||||||
| 2026-08-17 | UPLOAD | filename1.pdf | 0000000000-26-008092 | 333-298266 | 146483 | |||||
| 2026-08-14 | 4 | xslF345X06/form4-08152026_120800.xml | 0001725092-26-000013 | 18551 | ||||||
| 2026-08-14 | 144 | xsl144X01/primary_doc.xml | 0001725092-26-000011 | 001-38327 | 261284438 | 33 | 5692 | |||
| 2026-08-14 | 10-Q | 10-Q | 0001193125-26-352128 | 001-38327 | 261280892 | 34 | 11426664 | 1 | 1 | |
| 2026-08-14 | 8-K | 8-K | 2.02 | 0001193125-26-352126 | 001-38327 | 261280847 | 34 | 413409 | 1 | 1 |
| 2026-08-14 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000938206-26-000041 | 005-90232 | 261276099 | 34 | 7449 | |||
| 2026-08-13 | 144 | xsl144X01/primary_doc.xml | 0001579629-26-000006 | 001-38327 | 261275736 | 33 | 5003 | |||
| 2026-08-12 | S-3 | S-3 | 0001193125-26-346867 | 333-298266 | 261267611 | 33 | 384812 | 1 | 1 | |
| 2026-08-03 | 8-K | 8-K | 5.02 | 0001193125-26-330730 | 001-38327 | 261233841 | 34 | 147195 | 1 | 1 |
| 2026-08-03 | 4 | xslF345X06/form4-08032026_080815.xml | 0001320383-26-000006 | 7441 | ||||||
| 2026-08-03 | 3 | xslF345X06/form3-08032026_080851.xml | 0001320383-26-000004 | 16500 | ||||||
| 2026-07-30 | 4/A | xslF345X06/form4a-07302026_080752.xml | 0001725092-26-000009 | 9393 | ||||||
| 2026-07-22 | D | xslFormDX01/primary_doc.xml | 06b | 0001645460-26-000004 | 021-591745 | 261192975 | 33 | 11349 | ||
| 2026-07-15 | 4 | xslF345X06/form4-07152026_100742.xml | 0002008790-26-000006 | 7504 | ||||||
| 2026-07-15 | 3 | xslF345X06/form3-07152026_100719.xml | 0002008790-26-000004 | 16337 | ||||||
| 2026-07-10 | 4 | xslF345X06/form4-07102026_110755.xml | 0001974756-26-000004 | 5075 | ||||||
| 2026-07-10 | 4 | xslF345X06/form4-07102026_110706.xml | 0001820365-26-000009 | 5078 | ||||||
| 2026-07-10 | 4 | xslF345X06/form4-07102026_110706.xml | 0002059447-26-000004 | 5276 | ||||||
| 2026-07-10 | 4 | xslF345X06/form4-07102026_110702.xml | 0002137444-26-000007 | 5081 | ||||||
| 2026-07-10 | 4 | xslF345X06/form4-07102026_110720.xml | 0002138368-26-000005 | 7823 | ||||||
| 2026-07-10 | 4 | xslF345X06/form4-07102026_110713.xml | 0001579629-26-000004 | 7823 | ||||||
| 2026-07-10 | 4 | xslF345X06/form4-07102026_110711.xml | 0001725092-26-000006 | 7806 | ||||||
| 2026-07-10 | 8-K | 8-K | 1.01,3.02,5.02,8.01,9.01 | 0001193125-26-301052 | 001-38327 | 261169512 | 34 | 587017 | 1 | 1 |
| 2026-07-01 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-002180 | 333-296896 | 261147581 | 33 | 1787 | ||
| 2026-06-29 | CORRESP | filename1.htm | 0001193125-26-288417 | 8371 | ||||||
| 2026-06-25 | UPLOAD | filename1.pdf | 0000000000-26-006372 | 333-296896 | 145566 | |||||
| 2026-06-18 | S-3 | S-3 | 0001193125-26-275808 | 333-296896 | 261102523 | 33 | 434031 | 1 | 1 | |
| 2026-06-17 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-002046 | 333-296456 | 261100279 | 33 | 1787 | ||
| 2026-06-15 | CORRESP | filename1.htm | 0001193125-26-271175 | 8073 | ||||||
| 2026-06-11 | 3 | xslF345X06/form3-06112026_090651.xml | 0002138368-26-000003 | 3289 | ||||||
| 2026-06-11 | 3 | xslF345X06/form3-06112026_090627.xml | 0001579629-26-000002 | 5240 | ||||||
| 2026-06-10 | UPLOAD | filename1.pdf | 0000000000-26-005827 | 333-296456 | 145800 | |||||
| 2026-06-08 | 4 | xslF345X06/form4-06082026_080603.xml | 0001820365-26-000006 | 5615 | ||||||
| 2026-06-08 | 3 | xslF345X06/form3-06082026_080650.xml | 0001820365-26-000004 | 3263 | ||||||
| 2026-06-03 | 4 | xslF345X06/form4-06032026_090611.xml | 0001725092-26-000004 | 8829 | ||||||
| 2026-06-03 | 8-K | 8-K | 5.02,5.07,9.01 | 0001193125-26-255479 | 001-38327 | 261060860 | 34 | 209304 | 1 | 1 |
| 2026-06-03 | S-8 | S-8 | 0001193125-26-255427 | 333-296458 | 261060652 | 33 | 196984 | 1 | 1 | |
| 2026-06-03 | S-3 | S-3 | 0001193125-26-255418 | 333-296456 | 261060614 | 33 | 602839 | |||
| 2026-06-02 | 4 | xslF345X06/form4-06032026_120657.xml | 0002137444-26-000005 | 5619 | ||||||
| 2026-06-02 | 3 | xslF345X06/form3-06032026_120656.xml | 0002137444-26-000004 | 16365 | ||||||
| 2026-06-02 | 8-K | 8-K | 5.02,8.01 | 0001193125-26-253709 | 001-38327 | 261056983 | 34 | 151348 | 1 | 1 |
| 2026-05-21 | DEF 14A | DEF 14A | 0001193125-26-233369 | 001-38327 | 261006064 | 34 | 980513 | |||
| 2026-05-14 | 8-K | 8-K | 9.01 | 0001193125-26-224101 | 001-38327 | 26979276 | 34 | 364274 | 1 | 1 |
| 2026-05-14 | 10-Q | 10-Q | 0001193125-26-224091 | 001-38327 | 26979253 | 34 | 8380673 | 1 | 1 | |
| 2026-05-14 | D | xslFormDX01/primary_doc.xml | 06b | 0001645460-26-000003 | 021-584091 | 26978965 | 33 | 13254 | ||
| 2026-05-11 | PRE 14A | PRE 14A | 0001193125-26-217130 | 001-38327 | 26965977 | 34 | 819997 | |||
| 2026-05-07 | 3 | 3 | 0001193125-26-211809 | 3116 | ||||||
| 2026-05-07 | 4 | 4 | 0001193125-26-211806 | 6815 | ||||||
| 2026-05-01 | S-8 | S-8 | 0001193125-26-198622 | 333-295482 | 26928440 | 33 | 273747 | 1 | 1 | |
| 2026-05-01 | 8-K | 8-K | 1.01,3.02,5.02,8.01,9.01 | 0001193125-26-198588 | 001-38327 | 26928388 | 34 | 1368820 | 1 | 1 |
| 2026-04-22 | 8-K | 8-K | 3.03,5.03 | 0001193125-26-168907 | 001-38327 | 26881471 | 34 | 252731 | 1 | 1 |
| 2026-04-13 | 8-K | 8-K | 5.07 | 0001193125-26-152826 | 001-38327 | 26857772 | 34 | 227909 | 1 | 1 |
| 2026-04-10 | 4 | 4 | 0001193125-26-151202 | 5453 | ||||||
| 2026-04-10 | 4 | 4 | 0001193125-26-151201 | 5486 | ||||||
| 2026-04-10 | 4 | 4 | 0001193125-26-151200 | 5530 | ||||||
| 2026-04-07 | 8-K | 8-K | 8.01 | 0001193125-26-144569 | 001-38327 | 26842950 | 34 | 198976 | 1 | 1 |
| 2026-03-31 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-001020 | 333-294366 | 26824502 | 33 | 1786 | ||
| 2026-03-27 | CORRESP | filename1.htm | 0001193125-26-129018 | 5927 | ||||||
| 2026-03-27 | DEFA14A | DEFA14A | 0001193125-26-129007 | 001-38327 | 26807335 | 34 | 30438 | |||
| 2026-03-27 | 8-K | 8-K | 5.02 | 0001193125-26-128993 | 001-38327 | 26807248 | 34 | 145722 | 1 | 1 |
| 2026-03-23 | UPLOAD | filename1.pdf | 0000000000-26-002905 | 333-294366 | 40086 | |||||
| 2026-03-16 | S-3 | S-3 | 0001193125-26-108656 | 333-294366 | 26759949 | 33 | 1476422 | 1 | 1 | |
| 2026-03-16 | ARS | ARS | 0001193125-26-108307 | 001-38327 | 26756503 | 34 | 3728099 | |||
| 2026-03-16 | DEF 14A | DEF 14A | 0001193125-26-108301 | 001-38327 | 26756497 | 34 | 4762981 | 1 | 1 | |
| 2026-03-16 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-108292 | 001-38327 | 26756473 | 34 | 443531 | 1 | 1 |
| 2026-03-16 | 10-K | 10-K | 0001193125-26-108287 | 001-38327 | 26756468 | 34 | 15815970 | 1 | 1 | |
| 2026-03-06 | PRE 14A | PRE 14A | 0001193125-26-096441 | 001-38327 | 26730727 | 34 | 4812713 | 1 | 1 | |
| 2026-02-18 | 8-K | 8-K | 8.01 | 0001193125-26-056983 | 001-38327 | 26648050 | 34 | 199529 | 1 | 1 |
| 2026-02-12 | 8-K | 8-K | 5.02 | 0001193125-26-047717 | 001-38327 | 26623489 | 34 | 199388 | 1 | 1 |
| 2026-01-06 | 4 | 4 | 0001193125-26-004359 | 5354 | ||||||
| 2026-01-06 | 4 | 4 | 0001193125-26-004358 | 5523 | ||||||
| 2026-01-06 | 4 | 4 | 0001193125-26-004356 | 5391 | ||||||
| 2026-01-06 | 4 | 4 | 0001193125-26-004357 | 5348 | ||||||
| 2026-01-06 | 4 | 4 | 0001193125-26-004355 | 5397 | ||||||
| 2026-01-06 | 4 | 4 | 0001193125-26-004354 | 5385 | ||||||
| 2026-01-02 | 4 | 4 | 0001193125-26-000900 | 9890 | ||||||
| 2025-12-29 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-010720 | 001-38327 | 251609050 | 33 | 4690 | |||
| 2025-12-19 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-25-326925 | 001-38327 | 251587859 | 34 | 651973 | 1 | 1 |
| 2025-12-19 | 424B5 | 424B5 | 0001193125-25-326847 | 333-271786 | 251587636 | 33 | 605937 | |||
| 2025-12-18 | 424B5 | 424B5 | 0001193125-25-324820 | 333-271786 | 251583173 | 33 | 608055 | |||
| 2025-12-05 | 4 | 4 | 0001193125-25-310067 | 7760 | ||||||
| 2025-11-25 | 4 | 4 | 0001193125-25-296986 | 5247 | ||||||
| 2025-11-25 | 4 | 4 | 0001193125-25-296985 | 5288 | ||||||
| 2025-11-24 | 8-K | 8-K | 7.01 | 0001193125-25-292093 | 001-38327 | 251509636 | 34 | 15459987 | 1 | 1 |
| 2025-11-20 | 8-K | 8-K | 5.02 | 0001193125-25-289713 | 001-38327 | 251502921 | 34 | 196215 | 1 | 1 |
| 2025-11-12 | 10-Q | 10-Q | 0001193125-25-277466 | 001-38327 | 251472387 | 34 | 9065284 | 1 | 1 | |
| 2025-11-12 | 8-K | 8-K | 2.02,9.01 | 0001193125-25-277468 | 001-38327 | 251472373 | 34 | 407599 | 1 | 1 |
| 2025-11-06 | 8-K | 8-K | 1.01,7.01,9.01 | 0001193125-25-268135 | 001-38327 | 251456267 | 34 | 306079 | 1 | 1 |
| 2025-10-02 | 4 | 4 | 0001193125-25-228920 | 5285 | ||||||
| 2025-10-02 | 3 | 3 | 0001193125-25-228919 | 21331 | ||||||
| 2025-09-29 | 8-K | 8-K | 5.02 | 0000950130-25-000140 | 001-38327 | 251355976 | 34 | 220321 | 1 | 1 |
| 2025-08-12 | S-8 | S-8 | 0000950170-25-107323 | 333-289528 | 251206816 | 33 | 370204 | 1 | 1 | |
| 2025-08-12 | 10-Q | 10-Q | 0000950170-25-107270 | 001-38327 | 251206471 | 34 | 8332355 | 1 | 1 | |
| 2025-08-12 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-107268 | 001-38327 | 251206460 | 34 | 544467 | 1 | 1 |
| 2025-07-01 | 8-K | 8-K | 1.01 | 0000950170-25-092168 | 001-38327 | 251096171 | 34 | 199104 | 1 | 1 |
| 2025-06-10 | 8-K | 8-K | 5.02,5.03,5.07,9.01 | 0000950170-25-084279 | 001-38327 | 251036993 | 34 | 504868 | 1 | 1 |
| 2025-06-06 | 4 | 4 | 0000950170-25-083026 | 5681 | ||||||
| 2025-06-06 | 3 | 3 | 0000950170-25-083025 | 12370 | ||||||
| 2025-05-27 | DEFA14A | DEFA14A | 0000950170-25-077389 | 001-38327 | 25984307 | 34 | 106655 | |||
| 2025-05-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001213900-25-044863 | 005-90232 | 25958891 | 34 | 21607 | |||
| 2025-05-12 | 10-Q | 10-Q | 0000950170-25-069125 | 001-38327 | 25934565 | 34 | 7928619 | 1 | 1 | |
| 2025-05-12 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-069124 | 001-38327 | 25934560 | 34 | 512293 | 1 | 1 |
| 2025-04-25 | ARS | ARS | 0000950170-25-058683 | 001-38327 | 25873613 | 34 | 18948254 | |||
| 2025-04-25 | DEF 14A | DEF 14A | 0000950170-25-058681 | 001-38327 | 25873611 | 34 | 4090615 | 1 | 1 | |
| 2025-04-25 | DEFA14A | DEFA14A | 0000950170-25-058677 | 001-38327 | 25873605 | 34 | 1040634 | |||
| 2025-04-15 | 8-K | 8-K | 1.01,2.02,8.01,9.01 | 0001193125-25-081592 | 001-38327 | 25840186 | 34 | 650376 | 1 | 1 |
| 2025-04-15 | 424B5 | 424B5 | 0001193125-25-081566 | 333-271786 | 25840147 | 33 | 585359 | |||
| 2025-04-14 | 424B5 | 424B5 | 0001193125-25-080293 | 333-271786 | 25836791 | 33 | 586882 | |||
| 2025-04-14 | 8-K | 8-K | 1.01 | 0001193125-25-080277 | 001-38327 | 25836651 | 34 | 146653 | 1 | 1 |
| 2025-04-14 | PRE 14A | PRE 14A | 0000950170-25-053694 | 001-38327 | 25835983 | 34 | 8518633 | 1 | 1 | |
| 2025-03-31 | S-8 | S-8 | 0000950170-25-047705 | 333-286258 | 25793263 | 33 | 237419 | |||
| 2025-03-31 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-047678 | 001-38327 | 25792979 | 34 | 402024 | 1 | 1 |
| 2025-03-31 | 10-K | 10-K | 0000950170-25-047677 | 001-38327 | 25792967 | 34 | 16385650 | 1 | 1 | |
| 2025-03-25 | 4 | 4 | 0000950170-25-044348 | 5277 | ||||||
| 2025-03-25 | 4 | 4 | 0000950170-25-044347 | 5274 | ||||||
| 2025-03-25 | 4 | 4 | 0000950170-25-044346 | 5310 | ||||||
| 2025-03-25 | 4 | 4 | 0000950170-25-044345 | 5236 | ||||||
| 2025-03-25 | 4 | 4 | 0000950170-25-044344 | 5307 | ||||||
| 2025-03-25 | 4 | 4 | 0000950170-25-044343 | 5312 | ||||||
| 2025-03-21 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001420506-25-000687 | 005-90232 | 25761937 | 34 | 15898 | |||
| 2025-03-12 | 8-K | 8-K | 5.02 | 0000950170-25-037885 | 001-38327 | 25731623 | 34 | 199245 | 1 | 1 |
| 2025-03-12 | 4 | 4 | 0000950170-25-037889 | 5551 | ||||||
| 2025-03-12 | 3 | 3 | 0000950170-25-037879 | 12176 | ||||||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-001077 | 005-90232 | 25630535 | 34 | 11464 | |||
| 2025-01-03 | 4 | 4 | 0000950170-25-001103 | 5546 | ||||||
| 2025-01-03 | 4 | 4 | 0000950170-25-001101 | 5540 | ||||||
| 2025-01-03 | 4 | 4 | 0000950170-25-001107 | 5497 | ||||||
| 2025-01-03 | 4 | 4 | 0000950170-25-001106 | 5427 | ||||||
| 2025-01-03 | 4 | 4 | 0000950170-25-001105 | 5501 | ||||||
| 2024-12-18 | 4 | 4 | 0000950170-24-137860 | 4992 | ||||||
| 2024-12-16 | UPLOAD | filename1.pdf | 0000000000-24-013826 | 001-38327 | 39566 | |||||
| 2024-12-11 | CORRESP | filename1.htm | 0001193125-24-275538 | 29676 | ||||||
| 2024-12-05 | UPLOAD | filename1.pdf | 0000000000-24-013392 | 001-38327 | 43293 | |||||
| 2024-11-29 | 4 | 4 | 0000950170-24-131890 | 5476 | ||||||
| 2024-11-29 | 3 | 3 | 0000950170-24-131889 | 11970 | ||||||
| 2024-11-14 | 10-Q | 10-Q | 0000950170-24-127005 | 001-38327 | 241461415 | 34 | 7635393 | 1 | 1 | |
| 2024-11-14 | 8-K | 8-K | 2.02 | 0000950170-24-127004 | 001-38327 | 241461381 | 34 | 345207 | 1 | 1 |
| 2024-10-08 | 8-K | 8-K | 5.03,5.07,9.01 | 0000950170-24-113520 | 001-38327 | 241360306 | 34 | 220016 | 1 | 1 |
| 2024-10-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001781002-24-000050 | 005-90232 | 241358561 | 34 | 10973 | |||
| 2024-10-04 | 8-K | 8-K | 1.01,9.01 | 0000950170-24-112887 | 001-38327 | 241354844 | 34 | 245772 | 1 | 1 |
| 2024-09-27 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-24-227977 | 001-38327 | 241335092 | 34 | 643306 | 1 | 1 |
| 2024-09-27 | 424B5 | 424B5 | 0001193125-24-227947 | 333-271786 | 241334876 | 33 | 598061 | |||
| 2024-09-26 | 424B5 | 424B5 | 0001193125-24-226974 | 333-271786 | 241329419 | 33 | 614858 | |||
| 2024-09-10 | DEF 14A | DEF 14A | 0000950170-24-105104 | 001-38327 | 241290022 | 34 | 673540 | |||
| 2024-09-05 | 3 | 3 | 0000950170-24-103956 | 11840 | ||||||
| 2024-09-05 | 4 | 4 | 0000950170-24-103955 | 5309 | ||||||
| 2024-09-03 | 8-K | 8-K | 5.02 | 0000950170-24-102851 | 001-38327 | 241274501 | 34 | 192042 | 1 | 1 |
| 2024-08-28 | PRE 14A | PRE 14A | 0000950170-24-101373 | 001-38327 | 241255226 | 34 | 666671 | |||
| 2024-08-16 | 8-K | 8-K | 3.01 | 0000950170-24-098032 | 001-38327 | 241216586 | 34 | 193052 | 1 | 1 |
| 2024-08-14 | 10-Q | 10-Q | 0000950170-24-096967 | 001-38327 | 241207185 | 34 | 7644336 | 1 | 1 | |
| 2024-07-25 | 8-K | 8-K | 5.02,8.01,9.01 | 0000950170-24-086476 | 001-38327 | 241141947 | 34 | 274325 | 1 | 1 |
| 2024-06-07 | 8-K | 8-K | 5.02,5.07 | 0000950170-24-070566 | 001-38327 | 241029132 | 34 | 219306 | 1 | 1 |
| 2024-06-07 | 4 | 4 | 0000950170-24-070565 | 5318 | ||||||
| 2024-06-07 | 4 | 4 | 0000950170-24-070564 | 5259 | ||||||
| 2024-06-07 | 4 | 4 | 0000950170-24-070563 | 5569 | ||||||
| 2024-06-07 | 4 | 4 | 0000950170-24-070562 | 5239 | ||||||
| 2024-06-07 | 3 | 3 | 0000950170-24-070561 | 14159 | ||||||
| 2024-06-07 | 4 | 4 | 0000950170-24-070559 | 5280 | ||||||
| 2024-05-24 | DEFA14A | DEFA14A | 0000950170-24-064528 | 001-38327 | 24984085 | 34 | 262447 | |||
| 2024-05-09 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-056848 | 001-38327 | 24930309 | 34 | 332092 | 1 | 1 |
| 2024-05-09 | 10-Q | 10-Q | 0000950170-24-056838 | 001-38327 | 24930271 | 34 | 7586712 | 1 | 1 | |
| 2024-04-26 | DEF 14A | DEF 14A | 0000950170-24-049072 | 001-38327 | 24883427 | 34 | 1438185 | |||
| 2024-04-26 | DEFA14A | DEFA14A | 0000950170-24-049044 | 001-38327 | 24883227 | 34 | 289707 | |||
| 2024-04-26 | ARS | ARS | 0000950170-24-049039 | 001-38327 | 24883206 | 34 | 31930025 | |||
| 2024-03-28 | S-8 | S-8 | 0000950170-24-038084 | 333-278329 | 24799548 | 33 | 146771 | |||
| 2024-03-28 | 10-K | 10-K | 0000950170-24-038059 | 001-38327 | 24799154 | 34 | 12294132 | 1 | 1 | |
| 2024-03-11 | SC 13G | CUEBIOPHARMA13G | 0001781002-24-000025 | 005-90232 | 24739631 | 34 | 41268 | |||
| 2024-03-08 | 4 | 4 | 0000950170-24-028613 | 5242 | ||||||
| 2024-03-08 | 4 | 4 | 0000950170-24-028611 | 5259 | ||||||
| 2024-03-08 | 4 | 4 | 0000950170-24-028612 | 5283 | ||||||
| 2024-03-08 | 4 | 4 | 0000950170-24-028609 | 5280 | ||||||
| 2024-03-08 | 4 | 4 | 0000950170-24-028608 | 5318 | ||||||
| 2024-02-22 | 4 | 4 | 0000950170-24-018724 | 5495 | ||||||
| 2024-02-07 | SC 13G | us22978p1066_020724.txt | 0001086364-24-006803 | 005-90232 | 24605674 | 34 | 12461 | |||
| 2024-01-31 | SC 13G | us22978p1066_013124.txt | 0001086364-24-006036 | 005-90232 | 24582172 | 34 | 13323 | |||
| 2024-01-04 | 4 | 4 | 0000950170-24-001833 | 5460 | ||||||
| 2024-01-04 | 4 | 4 | 0000950170-24-001830 | 5421 | ||||||
| 2024-01-04 | 4 | 4 | 0000950170-24-001829 | 5347 | ||||||
| 2024-01-04 | 4 | 4 | 0000950170-24-001828 | 5466 | ||||||
| 2024-01-04 | 4 | 4 | 0000950170-24-001827 | 5417 | ||||||
| 2023-11-03 | 10-Q | 10-Q | 0000950170-23-058838 | 001-38327 | 231376523 | 34 | 8708703 | 1 | 1 | |
| 2023-09-14 | 8-K | 8-K | 5.02 | 0001193125-23-235298 | 001-38327 | 231255125 | 34 | 139029 | 1 | 1 |
| 2023-08-29 | 4 | FORM 4 SUBMISSION | 0001209191-23-047575 | 4552 | ||||||
| 2023-08-16 | 4 | FORM 4 SUBMISSION | 0001209191-23-046000 | 4574 | ||||||
| 2023-08-08 | 10-Q | 10-Q | 0000950170-23-039770 | 001-38327 | 231151137 | 34 | 9848637 | 1 | 1 | |
| 2023-07-25 | 4 | FORM 4 SUBMISSION | 0001209191-23-043278 | 5411 | ||||||
| 2023-07-25 | 4 | FORM 4 SUBMISSION | 0001209191-23-043277 | 5378 | ||||||
| 2023-07-25 | 4 | FORM 4 SUBMISSION | 0001209191-23-043276 | 5377 | ||||||
| 2023-07-25 | 4 | FORM 4 SUBMISSION | 0001209191-23-043274 | 5335 | ||||||
| 2023-07-25 | 4 | FORM 4 SUBMISSION | 0001209191-23-043273 | 5355 | ||||||
| 2023-06-09 | 8-K | 8-K | 5.07 | 0001193125-23-164491 | 001-38327 | 231005811 | 34 | 160808 | 1 | 1 |
| 2023-05-26 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2023-05-26 16:30:00 | 9999999995-23-001552 | 333-271786 | 23971253 | 33 | 1744 | ||
| 2023-05-24 | CORRESP | filename1.htm | 0001193125-23-152982 | 6173 | ||||||
| 2023-05-16 | UPLOAD | filename1.pdf | 0000000000-23-005199 | 40198 | ||||||
| 2023-05-09 | S-3 | S-3 | 0001193125-23-139563 | 333-271786 | 23903509 | 33 | 1400402 | |||
| 2023-05-09 | 10-Q | 10-Q | 0000950170-23-019646 | 001-38327 | 23902022 | 34 | 8980925 | 1 | 1 | |
| 2023-04-28 | ARS | ARS | 0001193125-23-126930 | 001-38327 | 23866144 | 34 | 21165047 | |||
| 2023-04-28 | DEFA14A | DEFA14A | 0001193125-23-126907 | 001-38327 | 23866049 | 34 | 350265 | |||
| 2023-04-28 | DEF 14A | DEF 14A | 0001193125-23-126883 | 001-38327 | 23865910 | 34 | 1779194 | |||
| 2023-04-25 | 3 | FORM 3 SUBMISSION | 0001209191-23-025525 | 7476 | ||||||
| 2023-04-25 | 8-K | 8-K | 5.02 | 0000950170-23-014246 | 001-38327 | 23841787 | 34 | 213429 | 1 | 1 |
| 2023-04-21 | 4 | FORM 4 SUBMISSION | 0001209191-23-025142 | 5380 | ||||||
| 2023-04-13 | 3 | FORM 3 SUBMISSION | 0001209191-23-024221 | 8086 | ||||||
| 2023-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-23-024220 | 5424 | ||||||
| 2023-04-12 | 8-K | 8-K | 5.02 | 0000950170-23-012492 | 001-38327 | 23814680 | 34 | 261433 | 1 | 1 |
| 2023-03-27 | 4 | FORM 4 SUBMISSION | 0001209191-23-021201 | 9108 | ||||||
| 2023-03-21 | S-8 | S-8 | 0000950170-23-008929 | 333-270718 | 23749727 | 33 | 211084 | |||
| 2023-03-21 | 10-K | 10-K | 0000950170-23-008927 | 001-38327 | 23749714 | 34 | 13582046 | 1 | 1 | |
| 2023-03-10 | 8-K | 8-K | 5.02 | 0000950170-23-007304 | 001-38327 | 23724054 | 34 | 211560 | 1 | 1 |
| 2023-02-21 | 4 | FORM 4 SUBMISSION | 0001209191-23-011270 | 5389 | ||||||
| 2023-02-21 | 4 | FORM 4 SUBMISSION | 0001209191-23-011255 | 5314 | ||||||
| 2023-02-21 | 4 | FORM 4 SUBMISSION | 0001209191-23-011249 | 5297 | ||||||
| 2023-02-21 | 4 | FORM 4 SUBMISSION | 0001209191-23-011247 | 5336 | ||||||
| 2023-02-21 | 4 | FORM 4 SUBMISSION | 0001209191-23-011245 | 5337 | ||||||
| 2023-02-14 | SC 13G | CUE BIOPHARMA, INC. | 0000902664-23-001667 | 005-90232 | 23623438 | 34 | 73770 | |||
| 2023-02-03 | SC 13G/A | Cue_Biopharma_Inc.txt | 0000093751-23-000136 | 005-90232 | 23584455 | 34 | 8257 | |||
| 2023-01-19 | 4 | FORM 4 SUBMISSION | 0001209191-23-003988 | 5372 | ||||||
| 2023-01-19 | 3 | FORM 3 SUBMISSION | 0001209191-23-003987 | 7093 | ||||||
| 2023-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-001796 | 5474 | ||||||
| 2023-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-001789 | 5478 | ||||||
| 2023-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-001785 | 5386 | ||||||
| 2023-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-001780 | 5490 | ||||||
| 2023-01-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-001776 | 5399 | ||||||
| 2022-12-30 | 424B7 | 424B7 | 0001193125-22-315454 | 333-268687 | 221502336 | 33 | 255019 | |||
| 2022-12-15 | 424B3 | 424B3 | 0001193125-22-305962 | 333-268687 | 221465360 | 33 | 425993 | |||
| 2022-12-14 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2022-12-14 16:00:00 | 9999999995-22-003541 | 333-268687 | 221463568 | 33 | 1745 | ||
| 2022-12-12 | CORRESP | filename1.htm | 0001193125-22-302735 | 5122 | ||||||
| 2022-12-09 | UPLOAD | filename1.pdf | 0000000000-22-013274 | 40172 | ||||||
| 2022-12-06 | S-3 | S-3 | 0001193125-22-299361 | 333-268687 | 221447655 | 33 | 562986 | |||
| 2022-12-02 | SC 13G/A | SC 13G/A | 0001104659-22-124192 | 005-90232 | 221443074 | 34 | 47826 | |||
| 2022-11-21 | D | xslFormDX01/primary_doc.xml | 06b | 0001645460-22-000005 | 021-465492 | 221405847 | 33 | 15423 | ||
| 2022-11-18 | SC 13G | sc13g13606cue_11182022.htm | 0000921895-22-003095 | 005-90232 | 221401937 | 34 | 146291 | |||
| 2022-11-15 | 8-K | 8-K | 1.01,3.02,8.01,9.01 | 0001193125-22-285792 | 001-38327 | 221391585 | 34 | 937494 | 1 | 1 |
| 2022-11-14 | 10-Q | 10-Q | 0000950170-22-024991 | 001-38327 | 221385337 | 34 | 9846530 | 1 | 1 | |
| 2022-08-23 | 4 | FORM 4 SUBMISSION | 0001209191-22-047161 | 8784 | ||||||
| 2022-08-04 | 10-Q | 10-Q | 0000950170-22-014747 | 001-38327 | 221136667 | 34 | 8968407 | 1 | 1 | |
| 2022-07-08 | SC 13G | us22978p1066_070822.txt | 0000834237-22-010285 | 005-90232 | 221075041 | 34 | 12263 | |||
| 2022-06-22 | 8-K | 8-K | 5.02 | 0001193125-22-178755 | 001-38327 | 221031993 | 34 | 143681 | 1 | 1 |
| 2022-06-16 | 4 | FORM 4 SUBMISSION | 0001209191-22-037394 | 8626 | ||||||
| 2022-06-10 | 8-K | 8-K | 5.07 | 0001193125-22-171921 | 001-38327 | 221008794 | 34 | 189509 | 1 | 1 |
| 2022-05-31 | 4 | FORM 4 SUBMISSION | 0001209191-22-032800 | 4465 | ||||||
| 2022-05-25 | 4 | FORM 4 SUBMISSION | 0001209191-22-031791 | 9047 | ||||||
| 2022-05-10 | 10-Q | 10-Q | 0000950170-22-008990 | 001-38327 | 22909921 | 34 | 7750429 | 1 | 1 | |
| 2022-04-29 | DEFA14A | DEFA14A | 0001193125-22-133541 | 001-38327 | 22875127 | 34 | 408304 | |||
| 2022-04-29 | DEF 14A | DEF 14A | 0001193125-22-133519 | 001-38327 | 22875032 | 34 | 1599435 | |||
| 2022-04-04 | 4 | FORM 4 SUBMISSION | 0001209191-22-022578 | 8705 | ||||||
| 2022-04-04 | 4 | FORM 4 SUBMISSION | 0001209191-22-022570 | 10296 | ||||||
| 2022-04-04 | 4 | FORM 4 SUBMISSION | 0001209191-22-022568 | 6285 | ||||||
| 2022-03-30 | 8-K | 8-K | 1.01,2.03,9.01 | 0001193125-22-089787 | 001-38327 | 22786546 | 34 | 442690 | 1 | 1 |
| 2022-03-29 | 4 | FORM 4 SUBMISSION | 0001209191-22-021502 | 5404 | ||||||
| 2022-03-29 | 4 | FORM 4 SUBMISSION | 0001209191-22-021458 | 7688 | ||||||
| 2022-03-29 | 4 | FORM 4 SUBMISSION | 0001209191-22-021456 | 7633 | ||||||
| 2022-03-29 | 4 | FORM 4 SUBMISSION | 0001209191-22-021454 | 5373 | ||||||
| 2022-03-29 | 4 | FORM 4 SUBMISSION | 0001209191-22-021449 | 5380 | ||||||
| 2022-03-29 | 4 | FORM 4 SUBMISSION | 0001209191-22-021446 | 7673 | ||||||
| 2022-03-16 | S-8 | S-8 | 0001193125-22-077352 | 333-263624 | 22745805 | 33 | 59752 | |||
| 2022-03-16 | 10-K | 10-K | 0000950170-22-003969 | 001-38327 | 22745804 | 34 | 11504396 | 1 | 1 | |
| 2022-02-18 | 8-K | 8-K | 1.01,2.03 | 0001193125-22-046662 | 001-38327 | 22653275 | 34 | 149884 | 1 | 1 |
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001104659-22-022907 | 005-90232 | 22632621 | 34 | 88986 | |||
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001104659-22-021636 | 005-90232 | 22625426 | 34 | 59421 | |||
| 2022-02-10 | SC 13G | CUE_BIOPHARMA_INC.txt | 0000093751-22-000136 | 005-90232 | 22612991 | 34 | 8474 | |||
| 2022-02-03 | SC 13G/A | us22978p1066_020322.txt | 0000834237-22-006474 | 005-90232 | 22589232 | 34 | 13333 | |||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0000899243-22-001069 | 5517 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0000899243-22-001052 | 5526 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0000899243-22-001051 | 5479 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0000899243-22-001050 | 5389 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0000899243-22-001046 | 5402 | ||||||
| 2022-01-05 | 4 | FORM 4 SUBMISSION | 0000899243-22-001045 | 5479 | ||||||
| 2022-01-04 | 4 | FORM 4 SUBMISSION | 0000899243-22-000537 | 5403 | ||||||
| 2022-01-04 | 3 | FORM 3 SUBMISSION | 0000899243-22-000530 | 7539 | ||||||
| 2021-12-21 | 4 | FORM 4 SUBMISSION | 0000899243-21-049172 | 5367 | ||||||
| 2021-11-17 | 4 | FORM 4 SUBMISSION | 0000899243-21-045070 | 15137 | ||||||
| 2021-11-17 | 4 | FORM 4 SUBMISSION | 0000899243-21-045069 | 9256 | ||||||
| 2021-11-15 | 4 | FORM 4 SUBMISSION | 0000899243-21-044603 | 9263 | ||||||
| 2021-11-15 | 8-K | 8-K | 7.01,9.01 | 0001193125-21-328969 | 001-38327 | 211406410 | 34 | 12019104 | 1 | 1 |
| 2021-11-09 | 10-Q | 10-Q | 0001564590-21-055766 | 001-38327 | 211392716 | 34 | 7589230 | 1 | 1 | |
| 2021-10-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-060022 | 8778 | ||||||
| 2021-10-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-060021 | 8780 | ||||||
| 2021-10-05 | 4 | FORM 4 SUBMISSION | 0001209191-21-059698 | 14995 | ||||||
| 2021-10-01 | 424B5 | 424B5 | 0001193125-21-289860 | 333-239357 | 211299883 | 33 | 324979 | |||
| 2021-10-01 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-21-289829 | 001-38327 | 211299756 | 34 | 418789 | 1 | 1 |
| 2021-10-01 | 424B5 | 424B5 | 0001193125-21-289821 | 333-239357 | 211299703 | 33 | 10218 | |||
| 2021-09-27 | 4 | FORM 4 SUBMISSION | 0001209191-21-057785 | 9263 | ||||||
| 2021-09-27 | 4 | FORM 4 SUBMISSION | 0001209191-21-057784 | 5155 | ||||||
| 2021-08-09 | 10-Q | 10-Q | 0001564590-21-042619 | 001-38327 | 211156466 | 34 | 6989204 | 1 | 1 | |
| 2021-06-14 | 8-K | 8-K | 5.07 | 0001564590-21-032772 | 001-38327 | 211014552 | 34 | 211436 | 1 | 1 |
| 2021-05-21 | EFFECT | xslEFFECTX01/primary_doc.xml | POS AM,0001193125-21-074981,2021-05-21 | 9999999995-21-002052 | 333-239357 | 21950955 | 33 | 1761 | ||
| 2021-05-21 | POS AM | POS AM | 0001193125-21-169269 | 333-239357 | 21949082 | 33 | 441122 | |||
| 2021-05-10 | 10-Q | 10-Q | 0001564590-21-026048 | 001-38327 | 21907218 | 34 | 6193319 | 1 | 1 | |
| 2021-04-26 | DEFA14A | DEFA14A | 0001564590-21-020527 | 001-38327 | 21853825 | 34 | 251160 | |||
| 2021-04-26 | DEF 14A | DEF 14A | 0001564590-21-020525 | 001-38327 | 21853740 | 34 | 2095275 | |||
| 2021-03-18 | 8-K | 8-K | 7.01,9.01 | 0001193125-21-084993 | 001-38327 | 21753132 | 34 | 12235021 | 1 | 1 |
| 2021-03-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-021293 | 15257 | ||||||
| 2021-03-09 | S-8 | S-8 | 0001193125-21-074995 | 333-254045 | 21726758 | 33 | 51951 | |||
| 2021-03-09 | POS AM | POS AM | 0001193125-21-074981 | 333-239357 | 21726665 | 33 | 438247 | |||
| 2021-03-09 | 10-K | 10-K | 0001564590-21-011777 | 001-38327 | 21726495 | 34 | 16182428 | 1 | 1 | |
| 2021-03-09 | POSASR | POSASR | 0001193125-21-074863 | 333-239357 | 21725762 | 33 | 450323 | |||
| 2021-02-18 | 4 | FORM 4 SUBMISSION | 0000899243-21-007232 | 19179 | ||||||
| 2021-02-18 | 4/A | FORM 4/A SUBMISSION | 0000899243-21-007230 | 9799 | ||||||
| 2021-02-16 | SC 13G | SC 13G | 0001193125-21-043231 | 005-90232 | 21632120 | 34 | 83189 | |||
| 2021-02-12 | 4 | FORM 4 SUBMISSION | 0000899243-21-006362 | 5368 | ||||||
| 2021-02-12 | 4 | FORM 4 SUBMISSION | 0000899243-21-006360 | 5324 | ||||||
| 2021-02-12 | 4 | FORM 4 SUBMISSION | 0000899243-21-006358 | 5352 | ||||||
| 2021-02-12 | 4 | FORM 4 SUBMISSION | 0000899243-21-006355 | 5314 | ||||||
| 2021-02-12 | 4 | FORM 4 SUBMISSION | 0000899243-21-006354 | 5327 | ||||||
| 2021-02-12 | SC 13G/A | SC 13G/A | 0001104659-21-021772 | 005-90232 | 21626310 | 34 | 49611 | |||
| 2021-02-12 | SC 13G/A | CUE BIOPHARMA, INC. | 0000902664-21-001246 | 005-90232 | 21622931 | 34 | 58312 | |||
| 2021-02-01 | 5 | FORM 5 SUBMISSION | 0000899243-21-003885 | 9739 | ||||||
| 2021-01-29 | SC 13G/A | us22978p1066_012921.txt | 0000834237-21-003903 | 005-90232 | 21568742 | 34 | 13285 | |||
| 2021-01-22 | 4 | FORM 4 SUBMISSION | 0000899243-21-002947 | 5148 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0000899243-21-000712 | 5527 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0000899243-21-000711 | 5525 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0000899243-21-000710 | 5406 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0000899243-21-000705 | 5478 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0000899243-21-000702 | 5516 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0000899243-21-000701 | 5478 | ||||||
| 2021-01-06 | 4 | FORM 4 SUBMISSION | 0000899243-21-000700 | 5388 | ||||||
| 2020-11-25 | 4 | FORM 4 SUBMISSION | 0000899243-20-032155 | 5778 | ||||||
| 2020-11-19 | 8-K | 8-K | 1.01 | 0001193125-20-297603 | 001-38327 | 201327131 | 34 | 145227 | 1 | 1 |
| 2020-11-09 | 10-Q | 10-Q Q3 2020 | 0001564590-20-052490 | 001-38327 | 201297708 | 34 | 7324872 | 1 | 1 | |
| 2020-10-06 | 4 | FORM 4 SUBMISSION | 0000899243-20-027608 | 8784 | ||||||
| 2020-10-01 | 4 | FORM 4 SUBMISSION | 0000899243-20-026662 | 6577 | ||||||
| 2020-09-18 | 4 | FORM 4 SUBMISSION | 0001209191-20-051145 | 5177 | ||||||
| 2020-09-18 | 3 | FORM 3 SUBMISSION | 0001209191-20-051142 | 6793 | ||||||
| 2020-09-17 | 8-K | 8-K | 5.02 | 0001193125-20-247622 | 001-38327 | 201180129 | 34 | 145000 | 1 | 1 |
| 2020-08-25 | 4 | FORM 4 SUBMISSION | 0001209191-20-048212 | 13261 | ||||||
| 2020-08-24 | 8-K | 8-K | 1.01,5.02,9.01 | 0001193125-20-228378 | 001-38327 | 201128108 | 34 | 246656 | 1 | 1 |
| 2020-08-10 | 4/A | FORM 4/A SUBMISSION | 0001209191-20-045921 | 9625 | ||||||
| 2020-08-07 | 10-Q | 10-Q Q2 2020 CUE | 0001564590-20-038375 | 001-38327 | 201085726 | 34 | 7232856 | 1 | 1 | |
| 2020-08-07 | 4 | FORM 4 SUBMISSION | 0001209191-20-045702 | 9162 | ||||||
| 2020-08-07 | 4 | FORM 4 SUBMISSION | 0001209191-20-045698 | 8624 | ||||||
| 2020-08-05 | 4 | FORM 4 SUBMISSION | 0001209191-20-045144 | 14939 | ||||||
| 2020-08-05 | 4 | FORM 4 SUBMISSION | 0001209191-20-045142 | 18254 | ||||||
| 2020-07-15 | 8-K | 8-K | 5.03,5.07,9.01 | 0001193125-20-193348 | 001-38327 | 201029525 | 34 | 33455 | ||
| 2020-06-26 | 8-K | 8-K | 1.01,9.01 | 0001193125-20-180915 | 001-38327 | 20994174 | 34 | 27786 | ||
| 2020-06-25 | 4 | FORM 4 SUBMISSION | 0001209191-20-038885 | 7864 | ||||||
| 2020-06-22 | 8-K | 8-K | 1.01,9.01 | 0001193125-20-175747 | 001-38327 | 20979688 | 34 | 197868 | ||
| 2020-06-22 | 424B5 | 424B5 | 0001193125-20-175737 | 333-239357 | 20979650 | 33 | 655804 | |||
| 2020-06-22 | S-3ASR | S-3ASR | 0001193125-20-175657 | 333-239357 | 20979350 | 33 | 770166 | |||
| 2020-06-05 | 8-K | 8-K | 7.01,9.01 | 0001193125-20-162176 | 001-38327 | 20946152 | 34 | 8672168 | ||
| 2020-05-29 | DEFA14A | DEFA14A | 0001193125-20-155724 | 001-38327 | 20927815 | 34 | 234243 | |||
| 2020-05-29 | DEF 14A | DEF 14A | 0001193125-20-155706 | 001-38327 | 20927694 | 34 | 562158 | |||
| 2020-05-19 | 8-K | 8-K | 2.02,9.01 | 0001193125-20-146121 | 001-38327 | 20893654 | 34 | 55603 | ||
| 2020-05-15 | PRE 14A | PRE 14A | 0001193125-20-143998 | 001-38327 | 20885592 | 34 | 561737 | |||
| 2020-05-12 | 4 | FORM 4 SUBMISSION | 0001209191-20-028490 | 5306 | ||||||
| 2020-05-07 | 10-Q | CUE-Q1-2020 | 0001564590-20-022851 | 001-38327 | 20856445 | 34 | 5079311 | 1 | ||
| 2020-04-29 | 10-K/A | 10-K/A | 0001193125-20-126402 | 001-38327 | 20831215 | 34 | 243333 | |||
| 2020-04-21 | SC 13D/A | formsc13da.htm | 0001493152-20-006833 | 005-90232 | 20805004 | 34 | 52414 | |||
| 2020-04-10 | 4 | FORM 4 SUBMISSION | 0001209191-20-024164 | 10821 | ||||||
| 2020-03-27 | 8-K | 8-K | 1.01,9.01 | 0001193125-20-088890 | 001-38327 | 20752554 | 34 | 201238 | ||
| 2020-03-27 | 424B5 | 424B5 | 0001193125-20-088881 | 333-229140 | 20752516 | 33 | 712925 | |||
| 2020-03-26 | 4 | FORM 4 SUBMISSION | 0001209191-20-021239 | 5345 | ||||||
| 2020-03-17 | 8-K | 8-K | 2.02,9.01 | 0001193125-20-076018 | 001-38327 | 20721291 | 34 | 73694 | ||
| 2020-03-12 | S-8 | S-8 | 0001193125-20-071746 | 333-237140 | 20709871 | 33 | 58281 | |||
| 2020-03-12 | 10-K/A | 10-K/A | 0001193125-20-071718 | 001-38327 | 20709775 | 34 | 454334 | |||
| 2020-03-12 | 10-K | 10-K | 0001564590-20-010212 | 001-38327 | 20706956 | 34 | 8294237 | 1 | ||
| 2020-03-02 | 8-K | 8-K | 7.01,9.01 | 0001193125-20-058942 | 001-38327 | 20677151 | 34 | 9616596 | ||
| 2020-02-24 | 4/A | FORM 4/A SUBMISSION | 0001209191-20-012027 | 7173 | ||||||
| 2020-02-14 | SC 13G | SC 13G | 0001104659-20-021215 | 005-90232 | 20616684 | 34 | 49355 | |||
| 2020-02-14 | SC 13G | CUE BIOPHARMA, INC. | 0000902664-20-001125 | 005-90232 | 20615222 | 34 | 63508 | |||
| 2020-02-12 | 4 | FORM 4 SUBMISSION | 0001209191-20-008815 | 5325 | ||||||
| 2020-02-12 | 4 | FORM 4 SUBMISSION | 0001209191-20-008809 | 5330 | ||||||
| 2020-02-12 | 4 | FORM 4 SUBMISSION | 0001209191-20-008800 | 5319 | ||||||
| 2020-02-12 | 4 | FORM 4 SUBMISSION | 0001209191-20-008793 | 7777 | ||||||
| 2020-02-10 | 8-K | 8-K | 1.01,5.02,9.01 | 0001193125-20-029740 | 001-38327 | 20591848 | 34 | 96334 | ||
| 2020-02-07 | SC 13G | us22978p1066_020620.txt | 0000834237-20-008154 | 005-90232 | 20584800 | 34 | 13123 | |||
| 2020-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-20-002066 | 5336 | ||||||
| 2020-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-20-002064 | 5310 | ||||||
| 2020-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-20-002063 | 5347 | ||||||
| 2020-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-20-002061 | 5324 | ||||||
| 2020-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-20-002060 | 5334 | ||||||
| 2020-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-20-002058 | 5287 | ||||||
| 2020-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-20-002057 | 5215 | ||||||
| 2020-01-06 | 4 | FORM 4 SUBMISSION | 0001209191-20-002054 | 5348 | ||||||
| 2019-12-31 | 4 | FORM 4 SUBMISSION | 0001209191-19-062325 | 9602 | ||||||
| 2019-12-27 | 4 | FORM 4 SUBMISSION | 0001209191-19-062031 | 8127 | ||||||
| 2019-12-19 | 4 | FORM 4 SUBMISSION | 0001209191-19-061377 | 12101 | ||||||
| 2019-12-18 | SC 13D | formsc-13d.htm | 0001493152-19-019389 | 005-90232 | 191290859 | 34 | 67214 | |||
| 2019-11-26 | 8-K | 8-K | 1.01,1.02,9.01 | 0001193125-19-300091 | 001-38327 | 191247310 | 34 | 204512 | ||
| 2019-11-25 | 424B5 | 424B5 | 0001193125-19-300046 | 333-229140 | 191247121 | 33 | 672784 |
One latest value per concept from companyfacts (277 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 8.36M | 2026-11-13 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 52.00M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 5,466.2 | 2026-08-11 | S-3 | 2026-08-12 | 0001193125-26-346867 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 5,466.2 | 2026-08-11 | S-3 | 2026-08-12 | 0001193125-26-346867 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 39.58M | 2026-08-11 | S-3 | 2026-08-12 | 0001193125-26-346867 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-08-11 | S-3 | 2026-08-12 | 0001193125-26-346867 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-08-11 | S-3 | 2026-08-12 | 0001193125-26-346867 | |||
| us-gaap | AccountsPayableAndAccruedLiabilitiesCurrent | Accounts Payable and Accrued Liabilities, Current | USD | 1.17M | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-14 | 0001564590-18-013461 | |
| us-gaap | AccountsPayableAndOtherAccruedLiabilities | Accounts Payable and Other Accrued Liabilities | USD | 200,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 3.61M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 5.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AccruedEmployeeBenefitsCurrent | Accrued Employee Benefits, Current | USD | 1.76M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 15.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AccruedPayrollTaxesCurrentAndNoncurrent | Accrued Payroll Taxes | USD | 12.14M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 1.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 3.68M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | 1,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-277466 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 615.12M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 59.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 8.40M | 2017-01-01 | 2018-12-31 | 2020 | Q2 | 10-Q | 2020-08-07 | 0001564590-20-038375 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalWarrantIssued | Adjustments to Additional Paid in Capital, Warrant Issued | USD | 1,000 | 2017-01-01 | 2018-12-31 | 2020 | Q2 | 10-Q | 2020-08-07 | 0001564590-20-038375 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 59.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | AmortizationOfDebtDiscountPremium | Amortization of Debt Discount (Premium) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | AmortizationOfFinancingCosts | Amortization of Debt Issuance Costs | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | AmortizationOfIntangibleAssets | Amortization of Intangible Assets | USD | 11,666 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011777 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 4.28M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | Assets | Assets | USD | 67.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 66.71M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AssetsFairValueDisclosure | Assets, Fair Value Disclosure | USD | 57.40M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 1,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-277466 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 96,000 | 2022-12-31 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058838 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 6.97M | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-277466 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0000950170-25-047677 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 6.97M | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-277466 | |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 140.65M | 2020-01-01 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-07 | 0001564590-20-022851 |
| us-gaap | Cash | Cash | USD | 20.80M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001564590-19-007832 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 57.94M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | CashAndCashEquivalentsFairValueDisclosure | Cash and Cash Equivalents, Fair Value Disclosure | USD | 26.60M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | -10.43M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-14 | 0001564590-18-013461 |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 64.40M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-16 | 0000950170-22-003969 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 16.04M | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-13 | 0001564590-18-029316 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | 58.09M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | 30.80M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | CertificatesOfDepositAtCarryingValue | Certificates of Deposit, at Carrying Value | USD | 50,000 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-14 | 0001564590-18-013461 | |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 2.7 | 2015-06-15 | 2022 | Q3 | 10-Q | 2022-11-14 | 0000950170-22-024991 | |
| us-gaap | ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights | Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 551,724 | 2026-04-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 10.72M | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058838 | |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 5.62M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 300.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 7.75M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 7.75M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 8,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -208.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ContractWithCustomerLiabilityRevenueRecognized | Contract with Customer, Liability, Revenue Recognized | USD | 3.00M | 2021-11-23 | 2024 | FY | 10-K | 2025-03-31 | 0000950170-25-047677 | |
| us-gaap | DebtInstrumentCarryingAmount | Long-term Debt, Gross | USD | 5.00M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0000950170-24-127005 | |
| us-gaap | DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | USD | -37,000 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0000950170-24-127005 | |
| us-gaap | DebtSecuritiesTradingAndAvailableForSale | Debt Securities, Trading and Available-for-sale | USD | 6.97M | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-277466 | |
| us-gaap | DeferredFinanceCostsCurrentGross | Debt Issuance Costs, Gross, Current | USD | 9,000 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0000950170-24-127005 | |
| us-gaap | DeferredFinanceCostsNet | Debt Issuance Costs, Net | USD | 142,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | DeferredRentCredit | Deferred Rent Credit | USD | 9,000 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-14 | 0001564590-18-013461 | |
| us-gaap | DeferredRentCreditCurrent | Deferred Rent Credit, Current | USD | 381,465 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010212 | |
| us-gaap | DeferredTaxAssetsGoodwillAndIntangibleAssets | Deferred Tax Assets, Goodwill and Intangible Assets | USD | 4,000 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001564590-19-007832 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 96.82M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | DeferredTaxAssetsInProcessResearchAndDevelopment | Deferred Tax Assets, in Process Research and Development | USD | 19.76M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 933,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 60.65M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 988,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 5.06M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | USD | 1.11M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 95.89M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | DeferredTaxLiabilitiesOther | Deferred Tax Liabilities, Other | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0000950170-25-047677 | |
| us-gaap | DepositAssets | Deposit Assets | USD | 777,000 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-13 | 0001564590-18-029316 | |
| us-gaap | DepositsAssetsCurrent | Deposits Assets, Current | USD | 47,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | DepositsAssetsNoncurrent | Deposits Assets, Noncurrent | USD | 84,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | Depreciation | Depreciation | USD | 137,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | DepreciationAndAmortization | Depreciation, Depletion and Amortization, Nonproduction | USD | 635,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax | Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax | USD | 26.10M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -28.7 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -0.81 | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-04 | 0000950170-22-014747 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -28.7 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | -0.019 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.201 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | pure | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-16 | 0000950170-22-003969 |
| us-gaap | EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent | pure | -0.019 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.043 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | 0.002 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | -0.05 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0000950170-25-047677 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCredits | Effective Income Tax Rate Reconciliation, Tax Credit, Percent | pure | 0.02 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0000950170-25-047677 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.032 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 1.10M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-14 | 0001193125-26-224091 | |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | USD | 9.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | FinanceLeaseInterestExpense | Finance Lease, Interest Expense | USD | 200,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | GainLossOnDispositionOfAssets | Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | GainLossOnDispositionOfAssets1 | Gain (Loss) on Disposition of Assets | USD | 10,000 | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-14 | 0001193125-26-352128 |
| us-gaap | GainLossOnSaleOfPropertyPlantEquipment | Gain (Loss) on Disposition of Property Plant Equipment | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | GainLossOnTerminationOfLease | Gain (Loss) on Termination of Lease | USD | 120,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 80.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -53.01M | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-21 | 0000950170-23-008927 |
| us-gaap | IncomeTaxesPaid | Income Taxes Paid | USD | 0 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0000950170-22-024991 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 500,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 500,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncomeTaxPaidFederalAfterRefundReceived | IncomeTaxPaidFederalAfterRefundReceived | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncomeTaxPaidForeignAfterRefundReceived | IncomeTaxPaidForeignAfterRefundReceived | USD | 500,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncomeTaxPaidStateAndLocalAfterRefundReceived | IncomeTaxPaidStateAndLocalAfterRefundReceived | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 5.26M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncomeTaxReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount | USD | 500,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -5.48M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 1.13M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | -65,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 845,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -340,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | IncreaseDecreaseInAccountsPayableAndAccruedLiabilities | Increase (Decrease) in Accounts Payable and Accrued Liabilities | USD | -390,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-14 | 0001564590-18-013461 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | -414,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | IncreaseDecreaseInAccruedInterestReceivableNet | Increase (Decrease) in Accrued Interest Receivable, Net | USD | 0 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0000950170-24-127005 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 16.03M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | IncreaseDecreaseInDeposits | Increase (Decrease) in Deposits | USD | -551,000 | 2018-01-01 | 2018-06-30 | 2019 | Q2 | 10-Q | 2019-08-08 | 0001564590-19-030813 |
| us-gaap | IncreaseDecreaseInOtherCurrentAssets | Increase (Decrease) in Other Current Assets | USD | 184,000 | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-12 | 0000950170-25-107270 |
| us-gaap | IncreaseDecreaseInOtherOperatingAssets | Increase (Decrease) in Other Operating Assets | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-21 | 0000950170-23-008927 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 870,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | IndefiniteLivedTrademarks | Indefinite-Lived Trademarks | USD | 175,000 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-13 | 0001564590-18-029316 | |
| us-gaap | InterestExpense | Interest Expense | USD | 98,000 | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | InterestExpenseOther | Interest Expense, Other | USD | 200,000 | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | InterestIncomeExpenseNet | Interest Income (Expense), Net | USD | -11,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | InterestIncomeExpenseNonoperatingNet | Interest Income (Expense), Nonoperating, Net | USD | 819,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | IssuanceOfStockAndWarrantsForServicesOrClaims | Issuance of Stock and Warrants for Services or Claims | USD | 20.12M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | LandSubjectToGroundLeases | Land Subject to Ground Leases | sqft | 13,000 | 2022-03-28 | 2022 | Q1 | 10-Q | 2022-05-10 | 0000950170-22-008990 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 3.37M | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-14 | 0001193125-26-352128 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 921,000 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-14 | 0001193125-26-352128 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 559,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-277466 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 553,000 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-14 | 0001193125-26-352128 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 1.89M | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-14 | 0001193125-26-352128 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 1.17M | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-09 | 0001564590-20-052490 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 291,000 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-14 | 0001193125-26-352128 | |
| us-gaap | Liabilities | Liabilities | USD | 28.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 67.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 19.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | LongTermDebt | Long-term Debt | USD | 1.00M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0000950170-24-127005 | |
| us-gaap | LongTermDebtCurrent | Long-term Debt, Current Maturities | USD | 4.00M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0000950170-24-127005 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths | Long-Term Debt, Maturity, Year One | USD | 1.00M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0000950170-24-127005 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree | Long-Term Debt, Maturity, Year Three | USD | 4.00M | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058838 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo | Long-Term Debt, Maturity, Year Two | USD | 4.00M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-14 | 0000950170-24-127005 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear | Long-Term Debt, Maturity, Remainder of Fiscal Year | USD | 0 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0000950170-22-024991 | |
| us-gaap | LongTermDebtNoncurrent | Long-term Debt, Excluding Current Maturities | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0000950170-25-047677 | |
| us-gaap | LossOnSaleOfInvestments | Loss on Sale of Investments | USD | 612 | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010212 |
| us-gaap | MarketableSecurities | Marketable Securities | USD | 27.10M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 80.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -121,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | NetCashProvidedByUsedInInvestingActivitiesContinuingOperations | Net Cash Provided by (Used in) Investing Activities, Continuing Operations | USD | -673,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-14 | 0001564590-18-013461 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -50.03M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Net Cash Provided by (Used in) Operating Activities, Continuing Operations | USD | -9.76M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-14 | 0001564590-18-013461 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -208.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | NetInvestmentInLeaseAllowanceForCreditLossWriteoff | Net Investment in Lease, Allowance for Credit Loss, Writeoff | USD | 498,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | -68.12M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 153.84M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -140.15M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 2.57M | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058838 |
| us-gaap | OperatingLeaseLeaseIncome | Operating Lease, Lease Income | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0000950170-24-038059 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 3.08M | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-14 | 0001193125-26-352128 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 2.06M | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058838 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | OperatingLeaseRightOfUseAssetAmortizationExpense | Operating Lease, Right-of-Use Asset, Amortization Expense | USD | 883,839 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-21 | 0000950170-23-008927 |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 10.80B | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001564590-19-007832 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 822,000 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0000950170-22-024991 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFiveYears | Operating Leases, Future Minimum Payments, Due in Five Years | USD | 818,000 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0000950170-22-024991 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 2.80M | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0000950170-22-024991 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 2.86M | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0000950170-22-024991 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 3.37M | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0000950170-22-024991 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 904,000 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-13 | 0001564590-18-029316 | |
| us-gaap | OperatingLeasesRentExpenseNet | Operating Leases, Rent Expense, Net | USD | 3.31M | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0000950170-22-024991 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.098 | 2025-12-31 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 79,188 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010212 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 85,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax | USD | 1,000 | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | 259,000 | 2020-01-01 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-07 | 0001564590-20-022851 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | USD | -10,958 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001564590-19-007832 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010212 |
| us-gaap | OtherLoansPayable | Other Loans Payable | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | OtherLoansPayableCurrent | Other Loans Payable, Current | USD | 929,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | OtherLoansPayableLongTerm | Other Loans Payable, Long-term, Noncurrent | USD | 190,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-277466 | |
| us-gaap | OtherLongTermDebt | Other Long-term Debt | USD | 36,972 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-21 | 0000950170-23-008927 | |
| us-gaap | OtherLongTermDebtCurrent | Other Long-term Debt, Current | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | OtherNoncashExpense | Other Noncash Expense | USD | 30,000 | 2020-01-01 | 2020-03-31 | 2021 | Q1 | 10-Q | 2021-05-10 | 0001564590-21-026048 |
| us-gaap | OtherNoncashIncome | Other Noncash Income | USD | 68,000 | 2019-01-01 | 2019-09-30 | 2020 | Q3 | 10-Q | 2020-11-09 | 0001564590-20-052490 |
| us-gaap | OtherNoncashIncomeExpense | Other Noncash Income (Expense) | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-16 | 0000950170-22-003969 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -74,000 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-09 | 0001564590-20-052490 |
| us-gaap | OtherResearchAndDevelopmentExpense | Other Research and Development Expense | USD | 35.10M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | OtherShortTermBorrowings | Other Short-term Borrowings | USD | 100,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-277466 | |
| us-gaap | PaymentsForRepurchaseOfCommonStock | Payments for Repurchase of Common Stock | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0000950170-24-038059 |
| us-gaap | PaymentsOfDebtIssuanceCosts | Payments of Debt Issuance Costs | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0000950170-24-038059 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 4.16M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001564590-19-007832 |
| us-gaap | PaymentsToAcquireAvailableForSaleSecuritiesDebt | Payments to Acquire Debt Securities, Available-for-sale | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-16 | 0000950170-22-003969 |
| us-gaap | PaymentsToAcquireIntangibleAssets | Payments to Acquire Intangible Assets | USD | 175,000 | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001564590-19-007832 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 121,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | PaymentsToAcquireShortTermInvestments | Payments to Acquire Short-term Investments | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0000950170-24-038059 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 1.69M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | ProceedsFromDebtNetOfIssuanceCosts | Proceeds from Debt, Net of Issuance Costs | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 66.16M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001564590-19-007832 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 77.38M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ProceedsFromIssuanceOfDebt | Proceeds from Issuance of Debt | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0000950170-24-038059 |
| us-gaap | ProceedsFromIssuanceOfPrivatePlacement | Proceeds from Issuance of Private Placement | USD | 49.00M | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010212 |
| us-gaap | ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised | USD | 55 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-16 | 0000950170-22-003969 |
| us-gaap | ProceedsFromSaleOfPropertyPlantAndEquipment | Proceeds from Sale of Property, Plant, and Equipment | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 1.37M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ProceedsFromWarrantExercises | Proceeds from Warrant Exercises | USD | 1.90M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -208.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | PropertyPlantAndEquipmentDisposals | Property, Plant and Equipment, Disposals | USD | 0 | 2020-01-01 | 2020-06-30 | 2020 | Q2 | 10-Q | 2020-08-07 | 0001564590-20-038375 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 3.91M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 225,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | RepaymentsOfDebt | Repayments of Debt | USD | 100,000 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-12 | 0000950170-25-069125 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 72.92M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | RestrictedCash | Restricted Cash | USD | 150,000 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-09 | 0001564590-20-052490 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 50,068 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010212 | |
| us-gaap | RestrictedCashNoncurrent | Restricted Cash, Noncurrent | USD | 154,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | RestrictedStockAwardForfeitures | Restricted Stock Award, Forfeitures | USD | 200,000 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0000950170-24-038059 |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -576.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 13.70M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | RevenueRemainingPerformanceObligation | Revenue, Remaining Performance Obligation, Amount | USD | 2.50M | 2022-12-31 | 2022 | FY | 10-K | 2023-03-21 | 0000950170-23-008927 | |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 1.12M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0000950170-25-047677 |
| us-gaap | SecurityDepositLiability | Security Deposit Liability | USD | 595,000 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-09 | 0000950170-23-019646 | |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 59.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 10.1 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-14 | 0001193125-26-224091 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | shares | 52,500 | 2021-08-20 | 2022 | FY | 10-K | 2023-03-21 | 0000950170-23-008927 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | USD/shares | 14.98 | 2021-08-20 | 2022 | FY | 10-K | 2023-03-21 | 0000950170-23-008927 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | pure | 1.056 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | pure | 0.886 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.049 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.039 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 0 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-14 | 0001193125-26-224091 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 404,587 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 108.21 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period | shares | 27,225 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 120,380 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares | 4.90M | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-277466 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 1.49M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value | USD/shares | 0.82 | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-277466 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 1.71M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 48.76 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost | Share-based Payment Arrangement, Plan Modification, Incremental Cost | USD | 217,000 | 2020-01-01 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-07 | 0001564590-20-022851 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | shares | 0 | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058838 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 21.8 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | USD/shares | 230.78 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 28.15 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 29.93 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | ShortTermBorrowings | Short-term Debt | USD | 100,000 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-12 | 0000950170-25-069125 | |
| us-gaap | StockGrantedDuringPeriodValueSharebasedCompensation | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture | USD | 0 | 2022-04-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-04 | 0000950170-22-014747 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 38.40M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | StockIssuedDuringPeriodSharesNewIssues | Stock Issued During Period, Shares, New Issues | shares | 7.66M | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0000950170-24-038059 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 62,818 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 13.39M | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0000950170-25-047677 |
| us-gaap | StockIssuedDuringPeriodValueOther | Stock Issued During Period, Value, Other | USD | 10.81M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-31 | 0000950170-25-047677 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures | Stock Issued During Period, Value, Restricted Stock Award, Forfeitures | USD | 55 | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-21 | 0000950170-23-008927 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardGross | Stock Issued During Period, Value, Restricted Stock Award, Gross | USD | 0 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0000950170-24-038059 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 1.37M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | UnrealizedGainLossOnInvestments | Unrealized Gain (Loss) on Investments | USD | 96,000 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-28 | 0000950170-24-038059 |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 3.40M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 | |
| us-gaap | UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions | USD | 19,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 281,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108287 |
| us-gaap | ValueAddedTaxReceivableCurrent | Value Added Tax Receivable, Current | USD | 1.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 | |
| us-gaap | ValueAddedTaxReceivableNoncurrent | Value Added Tax Receivable, Noncurrent | USD | 1.90M | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-12 | 0000950170-25-107270 | |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 7.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 34.01M | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-04 | 0000950170-22-014747 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 7.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463755 |